Ensuring PBM Competition Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Ensuring PBM Competition Act (H.R. 6844) is a legislative proposal introduced in the 118th Congress aimed at addressing competition issues related to Pharmacy Benefit Managers (PBMs) within the health sector. The bill was referred to the Subcommittee on Health but did not advance further and is currently classified as failed or expired. No official summary or full text is available, limiting detailed analysis of its specific provisions or mechanisms.
H.R. 6844 sought to promote competition among Pharmacy Benefit Managers to potentially impact drug pricing and healthcare costs but did not progress beyond initial committee referral and is no longer active.
- The bill focuses on the health policy area, specifically targeting competition among Pharmacy Benefit Managers (PBMs).
- It was introduced in the House of Representatives during the 118th Congress and referred to the Subcommittee on Health.
- The bill did not advance past the subcommittee stage and is currently marked as failed or expired.
['Pharmacy Benefit Managers (PBMs)', 'Healthcare providers and organizations involved in prescription drug distribution', 'Patients and consumers who may be affected by PBM competition and drug pricing']
['Lack of available full text and official summary limits understanding of specific implementation details and enforcement mechanisms.', 'Potential challenges in oversight and regulatory authority due to absence of detailed provisions.', 'Unclear cost implications or funding mechanisms related to promoting PBM competition.']
The bill was introduced in the 118th Congress and referred to the House Subcommittee on Health. It did not progress further and is currently classified as failed or expired. No further legislative actions or debates are recorded, indicating limited congressional movement on this proposal during the session.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could influence drug pricing dynamics by altering PBM competition, potentially affecting insurance plans and pharmaceutical manufacturers.', 'Changes in PBM competition might impact healthcare costs and patient access to medications indirectly.']
Due to the absence of the full bill text and official summary, transparency is limited, making it difficult for the public and oversight bodies to evaluate the bill's detailed provisions, enforcement mechanisms, and fiscal impacts. This lack of information constrains effective monitoring and accountability.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.